Results 121 to 130 of about 18,058,309 (312)

Clinical vaccine development

open access: yesClinical and Experimental Vaccine Research, 2015
Vaccination is regarded as one of the biggest triumphs in the history of medicine. We are living in the most successful period of vaccine development. The accumulation of multidisciplinary knowledge and the investment of massive funding have enabled the development of vaccines against many infectious diseases as well as other diseases including ...
openaire   +2 more sources

Ultra‐Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal‐Labeling Platform for Cancer Radioembolization

open access: yesAdvanced Science, EarlyView.
Conjugated poly(imide dioxime)‐based microspheres establish a radiometal coordination‐driven conformational interlocked network with ultra‐high radiostability. This platform enables low‐temperature, multi‐radionuclide labeling for SPECT/PET/MRI imaging and radionuclide therapy. Mechanistic insights from EXAFS and DFT reveal enhanced stability, while in
Xiao Xu   +10 more
wiley   +1 more source

Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine

open access: yesVaccines
Background/objectives: This was a post hoc analysis of safety data across the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine clinical trial development program. Methods: Data from eight clinical trials in 46,913 immunocompetent adults
Kumar Ilangovan   +9 more
doaj   +1 more source

Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis

open access: yes, 2013
Improvement to the immunogenicity of DNA vaccines was evaluated in a Mycobacterium tuberculosis (MTB) infection mouse model examining the combined effects of nonlytic Fc-fused IL-7 DNA (IL-7-nFc) and Flt3-ligand fused Mtb32 (F-Mtb32) DNA.
조상래
core   +1 more source

IDB Group Selected Development Contributions 2016-2019

open access: yes, 2020
This infographic shows selected IDB Group\u27s contributions to the Sustainable Development Goals (SDGs) reported through the Group\u27s Corporate Results Framework between 2016 and ...
Inter-American Development Bank
core   +1 more source

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

open access: yesAdvanced Science, EarlyView.
Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv   +14 more
wiley   +1 more source

Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation

open access: yesSwiss Medical Weekly
AIMS OF THE STUDY: Marketing authorisation of the bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) for maternal vaccination was predominantly based on safety and efficacy findings from the pivotal global phase 3 Maternal ...
Emma Shittu   +4 more
doaj   +1 more source

Using recombinant DNA technology for the development of live-attenuated dengue vaccines

open access: yes, 2012
[[abstract]]Dramatic increases in dengue (DEN) incidence and disease severity have been reported, in great part due to the geographic expansion of . Aedes aegypti and . Aedes albopictus mosquitoes.
Lee, HC;Butler, M;Wu, SC
core   +1 more source

Artificial Intelligence‐Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae

open access: yesAdvanced Science, EarlyView.
Integrated artificial intelligence (AI) ensembles identify highly potent repurposed drugs against Streptococcus pneumoniae. Prospective virtual screening of 6747 drugs uncovers nine active candidates, including thiostrepton. This drug exhibits low picomolar potency and bypasses established resistance in multidrug‐resistant strains, demonstrating an ...
Joshua S. Fitch   +6 more
wiley   +1 more source

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine–naive adults ≥18 years of age in India: A phase 3 single-arm trial

open access: yesHuman Vaccines & Immunotherapeutics
Streptococcus pneumoniae is a leading cause of bacteremia, bacterial meningitis, and pneumonia. In India, there is an unmet need for an expanded valent pneumococcal conjugate vaccine (PCV) to protect older adults. This phase 3, single-arm study evaluated
Balachandra Giriappa   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy